PE20200727A1 - Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso - Google Patents

Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso

Info

Publication number
PE20200727A1
PE20200727A1 PE2020000280A PE2020000280A PE20200727A1 PE 20200727 A1 PE20200727 A1 PE 20200727A1 PE 2020000280 A PE2020000280 A PE 2020000280A PE 2020000280 A PE2020000280 A PE 2020000280A PE 20200727 A1 PE20200727 A1 PE 20200727A1
Authority
PE
Peru
Prior art keywords
cycloolefins
compounds substituted
heteroaromatic compounds
halo
independently
Prior art date
Application number
PE2020000280A
Other languages
English (en)
Inventor
Wei-Guo Su
Guangxiu Dai
Kun Xiao
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of PE20200727A1 publication Critical patent/PE20200727A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Referido a un compuesto de formula I, una sal farmaceuticamente aceptable del mismo, y/o solvatos, mezclas racemicas; en donde R1 es H, -OH, halo, C1-6alquilo, entre otros; cada R2 es independientemente H, deuterio, halo, -OH, entre otros; R3, R3', R4 y R4' son independientemente elegidos a partir de H, C1-C6 alquilo, C2-C6 alquenilo, entre otros; m es 0, 1, 2, 3, 4, 5 o 6; n es 0, 1 o 2. Tambien se refiere a preparacion de compuestos intermediarios, una composicion farmaceutica, y su uso en el tratamiento del cancer, tumor solido, neurogliocitoma, o tumor maligno hematologico.
PE2020000280A 2017-09-07 2018-09-07 Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso PE20200727A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710801364.3A CN109467538A (zh) 2017-09-07 2017-09-07 环烯烃取代的杂芳环类化合物及其用途
PCT/CN2018/104531 WO2019047909A1 (en) 2017-09-07 2018-09-07 HETEROAROMATIC COMPOUNDS SUBSTITUTED WITH CYCLOOLEFINS AND THEIR USE

Publications (1)

Publication Number Publication Date
PE20200727A1 true PE20200727A1 (es) 2020-07-23

Family

ID=65634832

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000280A PE20200727A1 (es) 2017-09-07 2018-09-07 Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso

Country Status (18)

Country Link
US (2) US11414390B2 (es)
EP (1) EP3679020A4 (es)
JP (2) JP7273030B6 (es)
KR (1) KR102566237B1 (es)
CN (6) CN109467538A (es)
AR (1) AR112794A1 (es)
AU (1) AU2018329047B2 (es)
BR (1) BR112020004563A2 (es)
CA (1) CA3073782A1 (es)
CL (1) CL2020000553A1 (es)
EA (1) EA202090653A1 (es)
IL (1) IL272923B2 (es)
MX (1) MX2020002505A (es)
PE (1) PE20200727A1 (es)
PH (1) PH12020500408A1 (es)
SG (1) SG11202001642WA (es)
TW (1) TWI816693B (es)
WO (1) WO2019047909A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
EP3678666A4 (en) 2017-09-07 2021-06-09 Augusta University Research Institute, Inc. SPECIFIC AKT3 ACTIVATOR AND USES THEREOF
WO2022095756A1 (zh) * 2020-11-09 2022-05-12 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
WO2023134686A1 (zh) * 2022-01-11 2023-07-20 正大天晴药业集团股份有限公司 一种1,3,5-三嗪衍生物的制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555154A (en) 1967-08-16 1971-01-12 Armour Pharma Preparations containing 6 - cycloalkylguanamines and methods for treating inflammatory conditions therewith
EP0361489A3 (en) 1988-09-30 1991-06-12 Chugai Seiyaku Kabushiki Kaisha Novel 3,4-diaminoquinoline and pyridine compounds
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
JP2008500046A (ja) 2004-05-24 2008-01-10 エクーシス インコーポレイテッド 動物用計測装置
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
KR101495611B1 (ko) * 2006-04-07 2015-02-25 메틸진 인코포레이티드 히스톤 데아세틸라아제의 억제제
US20100035863A1 (en) * 2006-09-12 2010-02-11 Ucb Pharma, S.A. 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions
EP2144877A1 (en) * 2007-04-04 2010-01-20 UCB Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
SG176978A1 (en) * 2009-06-25 2012-02-28 Amgen Inc Heterocyclic compounds and their uses
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2012003283A1 (en) * 2010-06-30 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
WO2012117048A1 (en) 2011-03-02 2012-09-07 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
BR112014005554A2 (pt) 2011-09-12 2017-03-21 Merck Patent Gmbh aminas de imidazol como moduladores de atividade de quinase
AU2012308681B2 (en) * 2011-09-12 2017-07-13 Merck Patent Gmbh Aminopyrimidine derivatives for use as modulators of kinase activity
DK2800743T3 (en) 2012-01-06 2018-06-14 Agios Pharmaceuticals Inc THERAPEUTIC ACTIVE RELATIONS AND PROCEDURES FOR USE THEREOF
AU2013336755B2 (en) * 2012-10-24 2017-07-20 Basf Se Herbicidal azines
CN103044469A (zh) 2012-11-30 2013-04-17 大连联化化学有限公司 一种制备环戊烯/环己烯-1-硼酸频哪醇酯的方法
US9862692B2 (en) 2013-01-23 2018-01-09 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105517996B (zh) * 2013-07-11 2019-03-26 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
BR112016000489A8 (pt) * 2013-07-11 2020-01-07 Agios Pharmaceuticals Inc composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
EP3019480B1 (en) 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
SG10201709187TA (en) 2013-08-02 2017-12-28 Agios Pharmaceuticals Inc Therapeutically active compounds and their methods of use
HUE039306T2 (hu) * 2013-11-01 2018-12-28 Novartis Ag Kináz inhibitor aminoheteroaril-benzamidok
CA2949785A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse For Medicinsk Forskning Mth1 inhibitors for treatment of cancer
JP6635949B2 (ja) * 2014-06-04 2020-01-29 トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング 炎症性および自己免疫性の病気の処置のためのｍｔｈ１阻害剤
DK3330258T3 (da) 2015-07-30 2021-08-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd 1, 3, 5-triazinderivat og fremgangsmåde til anvendelse af samme
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
IL299563A (en) 2015-12-04 2023-02-01 Agios Pharmaceuticals Inc Methods for the treatment of acute myeloid leukemia characterized by the presence of a mutant allele of IDH2 and the absence of a mutant allele of NRAS
WO2017096945A1 (zh) * 2015-12-07 2017-06-15 北京康美特科技股份有限公司 含硼有机硅化合物、太阳能电池组件用密封剂以及太阳能电池组件
IL307931A (en) 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as EHMT1 and EHMT2 inhibitors
CN107382840B (zh) 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
UA126586C2 (uk) 2017-08-15 2022-11-02 Еббві Інк. Макроциклічні інгібітори mcl-1 та способи їх застосування
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
PT3680243T (pt) 2017-09-07 2022-01-12 Eisai R&D Man Co Ltd Composto pentacíclico

Also Published As

Publication number Publication date
NZ762447A (en) 2023-09-29
CN116999441A (zh) 2023-11-07
EA202090653A1 (ru) 2021-02-03
BR112020004563A2 (pt) 2020-09-08
US20210363115A2 (en) 2021-11-25
CN117024363A (zh) 2023-11-10
JP2023103290A (ja) 2023-07-26
CN109467538A (zh) 2019-03-15
KR20200052321A (ko) 2020-05-14
CN117797156A (zh) 2024-04-02
KR102566237B1 (ko) 2023-08-14
TW201912632A (zh) 2019-04-01
EP3679020A1 (en) 2020-07-15
IL272923A (en) 2020-04-30
WO2019047909A1 (en) 2019-03-14
AU2018329047A1 (en) 2020-03-12
US20220372005A1 (en) 2022-11-24
IL272923B2 (en) 2023-06-01
CN111132967B (zh) 2023-08-04
US11414390B2 (en) 2022-08-16
CN117257809A (zh) 2023-12-22
CA3073782A1 (en) 2019-03-14
TWI816693B (zh) 2023-10-01
CL2020000553A1 (es) 2020-08-07
MX2020002505A (es) 2020-07-20
CN111132967A (zh) 2020-05-08
EP3679020A4 (en) 2021-05-05
PH12020500408A1 (en) 2021-03-01
JP7273030B2 (ja) 2023-05-12
JP7273030B6 (ja) 2024-02-15
AR112794A1 (es) 2019-12-11
US20210163426A1 (en) 2021-06-03
JP2020533319A (ja) 2020-11-19
SG11202001642WA (en) 2020-03-30
AU2018329047B2 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
PE20200727A1 (es) Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso
AR094784A1 (es) Compuestos de tubulisina, métodos para obtenerlos y uso
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20221910A1 (es) Derivados de pirazolilo utiles como agentes anticancerigenos
PE20230238A1 (es) Inhibidores de kras g12c
PE20171648A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la capsida del vhb
AR115885A1 (es) Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno
PE20200700A1 (es) Compuestos macrociclicos y usos de los mismos
AR112392A1 (es) Compuesto tricíclico de pirazol, su uso para fabricar un medicamento y composición farmaceutica que lo comprende
AR066882A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
PE20212303A1 (es) Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer
AR068512A1 (es) Derivados de 4-aril-1h-piridin-2-onas disustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central
CO2022002729A2 (es) Métodos de tratamiento del cáncer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrógenos
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
AR051795A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
AR066063A1 (es) Derivados de triazol que son antagonistas de smo
AR081725A1 (es) Derivados de oxadiazol, proceso de preparacion de los mismos, composicion farmaceutica que los contienen y su uso en el tratamiento del cancer
AR126701A1 (es) Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
PE20200341A1 (es) Composiciones y compuestos terapeuticos y metodos para utilizarlos
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos